Camena Bioscience closes $10m Series A financing as demand for DNA synthesis technology increases
Camena has also strengthened the Board of Directors with key appointments
Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, announced it has closed a $10m Series A financing round, led by Mercia. The new funding will be used to scale operations and continue development of its pioneering DNA synthesis platform, gSynth™.
Camena is the first company to offer this unique and highly accurate enzyme-based DNA synthesis technology. It has already signed commercial agreements with leading consumers of synthetic genes, securing a multi-million-pound revenue stream over the previous year.
Synthetic genes are widely used by researchers to understand the mechanisms of disease, and in the drug discovery process to combat them. However, the cost, time and accuracy of traditional DNA synthesis methods developed in the 1980s remains problematic, particularly when creating long or complex sequences of genes. Camena’s technology overcomes these limitations by using a wholly novel enzymatic technology to accurately produce synthetic DNA.
Camena’s CEO and co-founder is Steve Harvey, PhD, a leader in genomics research, and the CSO and co-founder is Derek Stemple, PhD, a world-renowned molecular biologist and previously a co-founder of TwistDX which was acquired by Alere (now a part of Abbott) in 2010.
Steve Harvey, CEO, Camena Bioscience, commented: “We are delighted to have closed this latest round of funding with Mercia, which provides further validation of Camena’s approach. The ability to read, write and manipulate DNA is the foundation of the synthetic biology value chain, yet developments in DNA synthesis have not kept pace with DNA sequencing and editing capabilities. Camena’s gSynth™ platform is revolutionising the DNA synthesis market by unlocking access to genes and accelerating discovery pipelines.
“As the focus on sustainability and supply-chain security become more acute, Camena is leading the way with a green synthesis technology and is already well positioned to serve this burgeoning market. The invention of next-generation DNA sequencing technologies transformed our ability to “read” DNA. Our goal is to enable our customers to “write” DNA with the same confidence and ease.”
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
Last viewed contents
New Phase II data show Novartis' ACZ885 gave better pain relief and flare prevention for patients with chronic gout
Celera Genomics Presents Preclinical Data on its Human Histone Deacetylase (HDAC) Inhibitor
New 'Chiral Vortex' of Light Reveals Molecular Mirror Images - The entirely new structure of light could help drug developers see their work more clearly than before
Category:Canola_diseases
Measuring glucose concentration without enzymes - Sensor of novel material an alternative for blood glucose measurement
Univar Czech s.r.o. acquires enzymes distribution business of Ekozym
Cheaper drugs, vaccines forecast as collaborations grow between developing countries' biotech firms - 'South-South' biotech collaborations boost health, economies: Study
Nanostructures in human teeth
Additional Data from Multiple Phase 1 and 2 Studies of S*BIO’s Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis - SB1518 Alleviates MF-Associated Splenomegaly and Shows No Myelosuppression and No Exacerbation of Cytopenias
